ARC, FDA continue exchanging ideas on amyloidosis

The Amyloidosis Research Consortium submitted a Voice of the Patient (see BioCentury, Dec. 7, 2015).

ARC President and CEO Isabelle Lousada told BioCentury that FDA also has reviewed draft guidance the group submitted on the clinical development of products to treat amyloid light chain (AL) amyloidosis. ARC expects to submit a final draft guidance to FDA in August concerning AL amyloidosis. ...